PURPOSE: The present multimodal neuroimaging study examined whether amyloid pathology and glucose metabolism are related to cortical volume loss over time in Alzheimer's disease (AD) patients and healthy elderly controls. METHODS: Structural MRI scans of eleven AD patients and ten controls were available at baseline and follow-up (mean interval 2.5 years). Change in brain structure over time was defined as percent change of cortical volume within seven a-priori defined regions that typically show the strongest structural loss in AD. In addition, two PET scans were performed at baseline: [(11)C]PIB to assess amyloid-β plaque load and [(18)F]FDG to assess glucose metabolism. [(11)C]PIB binding and [(18)F]FDG uptake were measured in the precuneus, a region in which both amyloid deposition and glucose hypometabolism occur early in the course of AD. RESULTS: While amyloid-β plaque load at baseline was not related to cortical volume loss over time in either group, glucose metabolism within the group of AD patients was significantly related to volume loss over time (rho = 0.56, p < 0.05). CONCLUSION: The present study shows that in a group of AD patients amyloid-β plaque load as measured by [(11)C]PIB behaves as a trait marker (i.e., all AD patients showed elevated levels of amyloid, not related to subsequent disease course), whilst hypometabolism as measured by [(18)F]FDG changed over time indicating that it could serve as a state marker that is predictive of neurodegeneration.
PURPOSE: The present multimodal neuroimaging study examined whether amyloid pathology and glucose metabolism are related to cortical volume loss over time in Alzheimer's disease (AD) patients and healthy elderly controls. METHODS: Structural MRI scans of eleven ADpatients and ten controls were available at baseline and follow-up (mean interval 2.5 years). Change in brain structure over time was defined as percent change of cortical volume within seven a-priori defined regions that typically show the strongest structural loss in AD. In addition, two PET scans were performed at baseline: [(11)C]PIB to assess amyloid-β plaque load and [(18)F]FDG to assess glucose metabolism. [(11)C]PIB binding and [(18)F]FDG uptake were measured in the precuneus, a region in which both amyloid deposition and glucose hypometabolism occur early in the course of AD. RESULTS: While amyloid-β plaque load at baseline was not related to cortical volume loss over time in either group, glucose metabolism within the group of ADpatients was significantly related to volume loss over time (rho = 0.56, p < 0.05). CONCLUSION: The present study shows that in a group of ADpatients amyloid-β plaque load as measured by [(11)C]PIB behaves as a trait marker (i.e., all ADpatients showed elevated levels of amyloid, not related to subsequent disease course), whilst hypometabolism as measured by [(18)F]FDG changed over time indicating that it could serve as a state marker that is predictive of neurodegeneration.
Authors: Nicolas Villain; Gaël Chételat; Blandine Grassiot; Pierrick Bourgeat; Gareth Jones; Kathryn A Ellis; David Ames; Ralph N Martins; Francis Eustache; Olivier Salvado; Colin L Masters; Christopher C Rowe; Victor L Villemagne Journal: Brain Date: 2012-05-23 Impact factor: 13.501
Authors: Victor L Villemagne; Kerryn E Pike; Gaël Chételat; Kathryn A Ellis; Rachel S Mulligan; Pierrick Bourgeat; Uwe Ackermann; Gareth Jones; Cassandra Szoeke; Olivier Salvado; Ralph Martins; Graeme O'Keefe; Chester A Mathis; William E Klunk; David Ames; Colin L Masters; Christopher C Rowe Journal: Ann Neurol Date: 2011-01 Impact factor: 10.422
Authors: Anne M Fagan; Denise Head; Aarti R Shah; Daniel Marcus; Mark Mintun; John C Morris; David M Holtzman Journal: Ann Neurol Date: 2009-02 Impact factor: 10.422
Authors: Claus Svarer; Karine Madsen; Steen G Hasselbalch; Lars H Pinborg; Steven Haugbøl; Vibe G Frøkjaer; Søren Holm; Olaf B Paulson; Gitte M Knudsen Journal: Neuroimage Date: 2004-12-09 Impact factor: 6.556
Authors: Victor L Villemagne; Samantha Burnham; Pierrick Bourgeat; Belinda Brown; Kathryn A Ellis; Olivier Salvado; Cassandra Szoeke; S Lance Macaulay; Ralph Martins; Paul Maruff; David Ames; Christopher C Rowe; Colin L Masters Journal: Lancet Neurol Date: 2013-03-08 Impact factor: 44.182
Authors: Yi Li; Juha O Rinne; Lisa Mosconi; Elizabeth Pirraglia; Henry Rusinek; Susan DeSanti; Nina Kemppainen; Kjell Någren; Byeong-Chae Kim; Wai Tsui; Mony J de Leon Journal: Eur J Nucl Med Mol Imaging Date: 2008-06-20 Impact factor: 9.236
Authors: Jihye Hwang; Chan Mi Kim; Seun Jeon; Jong Min Lee; Yun Jeong Hong; Jee Hoon Roh; Jae-Hong Lee; Jae-Young Koh; Duk L Na Journal: Alzheimers Dement (Amst) Date: 2015-12-28
Authors: Marion Ortner; René Drost; Dennis Hedderich; Oliver Goldhardt; Felix Müller-Sarnowski; Janine Diehl-Schmid; Hans Förstl; Igor Yakushev; Timo Grimmer Journal: BMC Neurol Date: 2019-10-31 Impact factor: 2.474